You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
349 Early safety and efficacy of a phase 1/2 open-label, multi-center trial of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN)

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 202012708
Dec 202045010
Jan 20211804
Feb 20211604
Mar 202140016
Apr 20213604
May 20211107
Jun 2021007
Jul 2021004
Aug 20210010
Sep 2021006
Oct 202128028
Nov 202120015
Dec 2021402
Jan 2022604
Feb 20221603
Mar 20221007
Apr 20222006
May 202216019
Jun 202222010
Jul 2022802
Aug 20222005
Sep 202224012
Oct 20221603
Nov 20222204
Dec 20222207
Jan 20231400
Feb 20233002
Mar 20232605
Apr 20231605
May 20231801
Jun 2023800
Jul 20231806
Aug 20233005
Sep 2023603
Oct 20231405
Nov 20232605
Dec 20233405
Jan 20241000
Feb 20242802
Mar 20242604
Apr 20242002
May 20242205
Jun 20243602
Jul 20242403
Aug 20242403
Total9770270